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SUSTAINED DRUG RELEASED FROM CONTACT LENS
J.A. FERREIRA, P. DE OLIVEIRA, P. M. DA SILVA, A. CARREIRA, H. GIL AND J.N.
MURTA
Abstract: This paper focuses on ophthalmic drug release from a loaded copoly-
mer: the drug is dispersed in the polymeric matrix and entrapped in particles. The
copolymer is based in 2-hydroxyethyl methacrylate co-methacrylic acid and silicone
is used to prepare the loaded particles. A mathematical model to simulate the drug
release is proposed and a qualitative analysis is performed. Experimental results are
compared with simulation results. Contact lens made from the presented copolymer
are expected to deliver drug at therapeutical levels for a few days.
Keywords: Ophthalmic drug delivery, Contact lenses, p-(HEMA/MAA), Reaction-
diffusion equation, Qualitative behaviour, Numerical simulation, Experimental re-
sults.
1. Introduction
Topical administration of eye drops into the anterior fornix of the con-
junctiva is by far the most common route of ocular drug delivery. The con-
junctival sac has a volume of approximately 15− 30µl, the natural tear film
volume is 7 − 8µl and the tear turn over at approximately 16% per minute
during a normal blink rate of 15 − 20 blinks per minute. When a drop is
instilled into the eye it is diluted by the lacrimal secretion and 95% is cleared
by the tear fluid, highly dependent on environmental conditions particularly
temperature and humidity. Drug can also be absorbed in significant con-
centrations into the circulation by the subconjunctival, stroma and, mainly,
via nasal and nasopharyngeal mucosa. As a consequence topical adminis-
tration is very inefficient because a substantial volume of administered drug
is lost, only about 5% penetrates though the cornea to reach the anterior
chamber. Consequently, the limitation of the efficiency of eye drops is its
short residence time in the tear film and consequently the rapid variation
of drug concentration. Moreover serious side effects can occur (for example
undesirable heart effects with beta-blockers, widely used to treat glaucoma)
([5], [10]).
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To avoid drug loss, side effects and also to improve the efficiency of drug
delivery, many researchers have proposed the use of therapeutical contact
lenses as a vehicle to deliver ophthalmic drugs. The main advantage of this
method is the possibility of controlling the drug delivery by means of the use
of polymeric matrices designed to achieve pre-defined performances.Several
techniques have been proposed in the literature ([4],[6], [9]). Without being
exhaustive we can mention the use of
(i) soaked simple contact lenses;
(ii) compound contact lenses with a hollow cavity;
(iii) entrapment of proteins, cells and drugs by polymerization of hydrogel
monomers in the presence of species to be entrapped or by direct dissolution.
As far as soaking a lens in a drug is concerned even if the method is
more efficient than the use of eye drops some disadvantages still occur. We
mention the limitation of the drug loading imposed by the solubility of the
drug in the matrix and a short delivery period of time. In fact the delay
in the delivery is only caused by the diffusion in the polymeric gel matrix
and this barrier seems not to be enough to increase the residence time in the
precorneal area. In the case of the simultaneous polymerization techniques
previously mentioned the main disadvantage is related to the possibility that
drug molecules loose their characteristics during the process.
To overcome these disadvantages some authors proposed recently to en-
capsulate drugs in particles which are entrapped in polymeric matrices [2],
[3].This technique not only avoid the lose of therapeutical properties of drug
molecules during polymerization but also creates an additional barrier to
drug delivery. The drug transport within the contact lens have in this case
two causes of resistance: the diffusion through the particles and the diffusion
through the polymeric matrix. As a consequence the drug release attains in
this case several days. The delivery rates can be tailored to a specific treat-
ment by controlling some of the variables of the problem as the particle and
drug loading as well as the diffusion coefficient of the matrix and the mass
transfer coefficient across the particle surface.
In a recent paper Gulsen and Chauhan ([3]) focussed on drug filled particles
entrapped in a p-HEMA gel. The authors present therein a complete study
of chemical and physical properties of the hydrogel matrix loaded with four
types of particles. Two of these were opaque - due to the desastibilization
or aggregation of particles- and consequently can not be used to design oph-
thalmic contact lenses. Two other hydrogels exhibited better transparency
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properties: to obtain 79% transparency, value close to the 87% transmit-
tance value of the pure p-HEMA gels, a silica shell was deposited on the
microemulsion drops. However some drawbacks are still present in these
loaded particles hydrogels:
(i) If the particles are not stabilized with the silica shell, there is a initial
burst release which is an increasing function of the initial drug load. A small
initial burst release is obtained only for small loads that can be inefficient for
therapeutical needs;
(ii) When the particles are stabilized with a silica shell there is a delay
period that can attain three or four days during which there is practically no
drug delivery.
To circumvent the above drawbacks in this paper is proposed to use silicone
to encapsulate an ophthalmic drug - flurbiprofen. The drug delivery from a
copolymer film prepared using 2-hydroxyethyl methacrylate co-methacrylic
acid (p-(HEMA/MAA)) is studied. The loading of a p-(HEMA/MAA) copoly-
mer is made dispersing drug in the polymeric matrix dissolving the drug
directly in the mixture of monomers and dispersing silicone particles encap-
sulating the ophthalmic drug in the polymeric matrix.
The experimental work is completed by a mathematical model with a closed
form solution which predicts, for every time t, the total amount of drug re-
leased by the contact lens. The model is represented by a system of partial
differential equations, coupled with appropriate initial and boundary con-
ditions, which describe the mechanisms of diffusion and transference in the
polymeric matrix loaded with particles. The system was solved by using
Laplace transforms. The closed form solution can be used not only to pre-
dict the total amount of delivered drug but also as a tool to design new
polymeric matrices that exhibit a certain pre-defined mass release profile.
In Section 2 the experimental work is presented. In Section 3 the math-
ematical model is established and the closed form solution is obtained. An
analysis of this solution leads to several qualitative conclusions concerning
the release profile of the therapeutical lenses based in the p-(HEMA/MAA)
copolymer. In Section 4 the mathematical predictions are compared with the
experimental profiles. Finally in section 5 some conclusions are presented.
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2. Experimental work
2.1. Materials and methods.
2.1.1. Materials. In order to synthesize the copolymer the monomers 2-
hydroxyethyl methacrylate [Aldrich (HEMA, 97%, CAS [868− 77− 9])], and
methacrylic acid, [Fluka (MAA, ≥ 98%, CAS [79 − 41 − 4])] were used.
Ethylene glycol dimethacrylate was acquired from Aldrich (EGDMA, 98%,
CAS [97 − 90 − 5]), and azobisisobutyronitrile from Fluka (AIBN, ≥ 98%,
CAS [78− 67− 1]). The monomers were purified with an alumina column.
The microemulsion was prepared by using triethoxy(octyl)silane (TEOS,
≥ 97.5%, CAS [2943−75−1] ), decane (99%, CAS [124−18−5]), hydrochloric
acid (HCl, 37%, CAS [7647− 01− 0]) from Aldrich, and Brij 35 from Acros
Organics (CAS [9002− 92− 0]).
The ophthalmic drug employed was flurbiprofen, (97%, Sigma, CAS [5104−
49 − 4]) and the drug release media was phosphate buffered saline solution
(PBS, pH= 7.4, Sigma).
2.1.2. Synthesis methods.
• Preparation of the silicone particles:
In order to prepare the particles, the following procedure was used
([3]). 1g of Brij 35 was dissolved in 10g of water. This solution was
heated to 600C and stirred at 700rpm. A second solution was prepared
by dissolving 0.10ml of TEOS and 2mg of flurbiprofen in 0.15ml of
decane. Afterwards, this solution was added to the previous mixture,
maintaining the temperature and stirring, until the mixture became
clear. Then, 10ml of 1N HCl solution was added, and the mixture
was kept at 600C, for 6 hours, with continuous stirring.
• Preparation of the copolymer 2-hydroxyethyl methacrylate co-methacrylic
acid:
In order to prepare the copolymer, 9.5g of HEMA, 0.5g of MAA,
0.04g of EGDMA (cross-linker) and 30mg of AIBN (initiator) were
mixed thoroughly, in a beaker. Into the previous solution were added
3ml of distilled water. This final solution was degassed by bubbling
it with nitrogen. The copolymers with drug in the polymeric matrix
were synthesized by dissolving flurbiprofen (1mg) directly into the
mixture of monomers.
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The solution was placed between two plates with teflon that were
separated by a silicone spacer (1mm of thickness). The polymerization
reaction was performed at 600C, during 24 hours. This film was cut
into circular samples with 1cm of diameter.
• Preparation of the copolymer 2-hydroxyethyl methacrylate co-methacrylic
acid containing the silicone particles:
To prepare the p-(HEMA/MAA) copolymers containing the silicone
particles, the procedure was the same described previously, but the
water added to the solution was replaced by the microemulsion con-
taining silicone particles.
2.1.3. Copolymers characterization.
• Water content:
Equilibrium water content assays were performed by placing a sam-
ple of p-(HEMA/MAA) copolymer in 10ml of PBS at 370C. After
24 hours, the water on the surface was removed, and the sample was
weighed until constant weight. These samples were dried, previously,
in a vacuum oven at 250C. All the experiments were carried out in
triplicate.
• SEM studies:
In order to determine the structure of the copolymer, and to identify
the particles, we performed scanning electron microscopy (SEM) (Jeol,
JSM-5310 model, Japan), at 15kV. We analyzed p-(HEMA/MAA)
copolymer with and without particles, these samples were dried and
coated with gold.
2.1.4. Drug release studies. The drug release assays for p-(HEMA/MAA)
samples were carried out in a conical tube containing 10ml of PBS. At pre-
defined times, an aliquot of 1ml was taken replacing it by the same volume
of PBS. The tube was placed in a thermal bath at 370C, with continuous
stirring.
The samples drug concentration was determined by Ultraviolet Spectroscopy
(UV-VIS Spectrophotometer, JASCO, V-530 model) at a wavelength of 247.5nm.
Release assays were performed for the 3 types of samples, and also for the
control samples. The control samples were used to correct any release that
it is not drug, such as unreacted monomer, by subtracting their value of
absorbance.
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2.2. Results.
2.2.1. Water content. The equilibrium water content in PBS at 370C was
determined by the ratio of the weight of water in the copolymer to the total
weight of the copolymer (hydration equilibrium).
The percentage of water content of the p-(HEMA/MAA) copolymer was
67.8 ± 2%. This percentage was between the values of the water content
required for contact lenses.
2.2.2. SEM images. In Figure 1 we show the cross section of a pure copoly-
mer with a magnification of 5000 × . As it can be observed, the surface
presents uniformity/homogeneity.
Figure 1. SEM image of the cross section of a pure copolymer,
at 5000× magnification.
The SEM image of the cross section of the copolymer with microemulsion
(Figure 2) disclosed the existence of particles entrapped in the polymeric ma-
trix with multiple sizes, which can reach, approximately, 100nm of minimum
diameter. During the SEM analysis, we also verified that the particles were
not distributed homogeneously in the copolymer.
3. Mathematical model
In this section we present a mathematical model to describe the drug release
of a contact lens prepared using the p-(HEMA/MAA) copolymer loaded with
the therapeutical drug dispersed in the polymeric matrix and in the silicone
particles. We consider the schematic illustration of the particle laden thera-
peutical lens represented in Figure 3. In order to simplify the presentation
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Figure 2. SEM image of the cross section of a copolymer with
particles, at 5000× magnification.
Figure 3. Schematic illustration of the ophthalmic lens inserted
in the eye.
we assume that the drug leaving the lens is immediately removed. More re-
alistic assumptions will be considered in Section 4. The mathematical model
is characterized by a system of partial differential equations coupled with ini-
tial and boundary conditions. The expressions of the concentrations in the
polymeric matrix and in the silicone particles will be obtained using Laplace
transforms. The dependence of the behaviour of such concentrations on the
parameters of the model will be analyzed in this section.
The lens has a width of 2ℓ and is completely immersed in water. During the
experiment a mechanism of removal of the released drug was used. The drug
entrapped in the complex formed by the hydrogel and particles is described
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by 

∂Cg
∂t
= D
∂2Cg
∂x2
−
∂Cb
∂t
x ∈ (−ℓ, ℓ), t > 0
∂Cb
∂t
= λ(Cg − Cb), x ∈ (−ℓ, ℓ), t > 0,
(1)
where Cg represents the drug concentration in the gel, Cb the drug concen-
tration in the particles, D the diffusion coefficient of the drug in the gel and
λ stands for the product of the mass transfer coefficient for drug transport
across the particle surface and the ratio between the surface and the volume
of particles. System (1) is completed with the initial conditions{
Cg(x, 0) = C0g
Cb(x, 0) = C0b,
(2)
where C0g is the initial concentration in the gel and the C0b the initial concen-
tration inside the particles. Along with (1) and (2) the boundary conditions

Cg(−ℓ, t) = CE
∂Cg
∂x
(0, t) = 0,
(3)
are also considered. We note that the first condition in (3) means that the
external drug concentration is constant. From an experimental point of view
this condition represents the fact that the concentration of drug in water is
kept constant by means of a renewal mechanism that takes place at fixed
interval of times. From an ophthalmic point of view a boundary condition of
type
D
∂Cg
∂x
(−ℓ, t) = α(Cg(−ℓ, t)− CE),
where α stands for a transference coefficient, is a more accurate description
of the clearance mechanisms in the precorneal area. The second condition
in (3) assumes symmetry in the drug concentration within the lens property.
This property is expected to be satisfied in the experiments carried on.
To solve(1) we use Laplace transforms in time. Let us represent by X the
Laplace transform of X. From (1), (2) we have

−C0g + pCg = D
d2Cg
dx2
+ C0b − pCb
−C0b + pCb = λ(Cg − Cb).
(4)
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Computing Cb from the second equation in (4) and replacing in the first
one we obtain
D
d2Cg
dx2
−
p(p+ 2λ)
p+ λ
Cg = −C0g − C0b
λ
p+ λ
, (5)
which has the general solution
Cg = F1e
k1x + F2e
k2x +
(p+ λ)C0g + λC0b
p(p+ 2λ)
, (6)
where F1, F2 are constants to be computed and k1, k2 are defined by
k1, k2 = ±
√
p(p+ 2λ)
D(p+ λ)
. (7)
Remark 1. We note that from the second equation in (1) we have
Cb = λ
∫ t
0
e−λ(t−τ)Cg(x, τ)dτ + e−λtC0b (8)
and replacing in the first equation in (1) we obtain
∂Cg
∂t
= D
∂2Cg
∂x2
− λ(Cg − λ
∫ t
0
e−λ(t−τ)Cg(x, τ)dτ) + λe−λtC0b. (9)
Using Laplace transform in this last equation and considering that the in-
tegral therein represents a convolution product we then have
−C0g + pCg = D
∂2Cg
∂x2
− λ(Cg −
λ
p+ λ
Cg) +
λ
p+ λ
C0b (10)
which leads to equation (5).
As
Cg(−ℓ, t) =
CE
p
(11)
and
∂Cg
∂x
(0, t) = 0, (12)
we can compute constants F1, F2 obtaining
Cg = (
CE
p
−
(p+ λ)C0g + λC0b
p(p+ 2λ)
)
cosh(k1x)
cosh(k1ℓ)
+
(p+ λ)C0g + λC0b
p(p+ 2λ)
, (13)
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that is
Cg =
CE(p+ 2λ)− C0g(p+ λ)− λC0b
p(p+ 2λ)
cosh(k1x)
cosh(k1ℓ)
+
(p+ λ)C0g + λC0b
p(p+ 2λ)
. (14)
To invert (14) we note that the first term in the right hand side is of form
f(x, p)
g(p)
,
where f and g can be seen as polynomials with an infinite number of factors
more exactly
f(x, p) = (CE(p+2λ)−C0g(p+λ)−λC0b)(1+
4k21x
2
π2
)(1+
4k21x
2
32π2
)(1+
4k21x
2
52π2
) . . .
(15)
and
g(p) = p(p+ 2λ)(1 +
4k21ℓ
2
π2
)(1 +
4k21ℓ
2
32π2
)(1 +
4k21ℓ
2
52π2
) . . . . (16)
Following Crank [1], we then have
Cg =
∞∑
n=0
f(x, an)
g′(an)
eant + e−2λt(
C0g − C0b
2
) + (
C0b + C0g
2
), (17)
where an, n = 0, 1, . . . , represent the roots of g(p) = 0 which may be real or
complex.
As
g(p) = p(p+ 2λ) cosh(k1ℓ) (18)
the roots are p = 0, p = −2λ and also the roots of equation
cosh(
√
p(p+ 2λ)
D(p+ λ)
ℓ) = 0, (19)
that is √
p(p+ 2λ)
D(p+ λ)
= ±
(2n+ 1)πi
2ℓ
, n = 0, 1, . . . (20)
which lead to
p =
−8λℓ2 −D(2n+ 1)2π2 ±
√
(8λℓ2)2 +D2(2n+ 1)4π4
8ℓ2
, n = 0, 1, . . . .
(21)
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Let us compute g
′
(p). As
g
′
(p) = (p+ 2λ) cosh(k1ℓ) + p cosh(k1ℓ) + p(p+ 2λ)senh(k1ℓ)(
dk1
dp
)ℓ (22)
we have 

g′(0) = 2λ
g′(−2λ) = −2λ
g
′
(an) = an(an + 2λ)(±i)(−1)
n(dk1
dp
) |an ℓ
(23)
where an are defined in (21). From (17) we then have
Cg(x, t) =
∞∑
n=0
(−1)nD cos(
(2n+ 1)πx
2ℓ
)
b(an)(2n+ 1)π(an + λ)
2
an(an + 2λ)ℓ2(a2n + 2λ
2 + 2anλ)
eant
+CE
(24)
where
b(an) = C
E(an + 2λ)− C
0g(an + λ)− λC
0b.
Considering that
an(an + 2λ)
D(an + λ)
= −
(2n+ 1)2π2
4ℓ2
(25)
we can give Cg the following form
Cg = CE +
∞∑
n=0
(−1)n+14 cos(
(2n+ 1)πx
2ℓ
)
b(an)(an + λ)e
ant
(2n+ 1)π(a2n + 2λ
2 + 2anλ)
. (26)
The total mass released during t units of time, M(t), is defined by
M(t) = −2D
∫ t
0
∂Cg
∂x
(ℓ, τ)dτ. (27)
Computing
∂Cg
∂x
(ℓ, τ) from (26) and replacing in (27) we have
M(t) = −
4D
ℓ
∞∑
n=0
CE(an + 2λ)− C
0g(an + λ)− λC
0b
an(a2n + 2λ
2 + 2anλ)
(an+λ)(e
ant−1). (28)
The behaviour of M(t) as function of the parameters CE, C0g, C0b, D and
λ, characterizing the polymeric matrix and the drug, is considered in what
follows.
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In Figure 4 are exhibited 3D plots of the mass M(t), for t = 1, C0g =
0.5, C0b = 0.25 and CE = 0, 0.25. The corresponding level curves are also
plotted in this figure. As expected, an increase of the exterior concentration
implies a decreasing of the released mass.
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Figure 4. The behaviour of M(t) as a function of λ and D for
CE = 0 ((a)) and CE = 0.25 ((b)).
In Figure 5 we consider the behaviour of M(t), for t = 1, CE = 0, C0g =
0.5, as function of D and λ, for increasing values of C0b. As expected such
increasing leads to an increasing of the released mass.
Assuming now that CE, λ and D are fixed we present in Figure 6 the plots
and the level curves of M(t), for t = 1, CE = 0, λ = 0.01, as function of C0g
and C0b when D increases. As D increases the mass M(1) also increases.
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Figure 5. The behaviour of M(t) as function of λ and D for
C0b = 0 ((a)) and C0b = 0.25 ((b)).
Let us now study the qualitative behaviour of M(t) given by (28) in some
particular cases:
(i) The initial drug concentrations in the gel and in the particles are the
same
In this case C0g = C0b and we have from (28)
M(t) =
4D
ℓ
(C0g − CE)
∞∑
n=0
(an + 2λ)(an + λ)
an[(an + λ)2 + λ2]
(eant − 1). (29)
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Figure 6. The mass M(t) as a function of C0b, C0g for D = 0.01
((a)) and D = 0.05 ((b)).
Replacing (25) in (29) we can give M(t) the following form
M(t) = −
D2
ℓ3
(C0g − CE)
∞∑
n=0
(2n+ 1)2π2(an + λ)
2
a2n[(an + λ)
2 + λ2]
(eant − 1). (30)
As an ≤ 0 we conclude from this last equation that, for each t, the
total released mass is an increasing function of C0g − CE. We deduce
from (30) that for C0g > CE, M ′(t) > 0 and M ′′(t) < 0. It can be
also established that M ′(0+) = +∞. This behaviour can be observed
in Figure 7, we plot M(t) as function of C0g − CE for D = λ = 0.05
for C0g = C0b = 0.5.
(ii) The lens has no particles
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Figure 7. The mass M(t) for C0g = 0.5, CE = 0, 0.15, 0.25.
Considering that in this case λ = 0 and C0b = 0 we obtain from (28)
M(t) =
4D
ℓ
(C0g − CE)
∞∑
n=0
eant − 1
an
. (31)
Equation (31) represents the total mass released from a polymeric
matrix in a diffusion process under boundary and initial conditions

Cg(x, 0) = C0g
Cg(−ℓ, t) = CE
∂Cg
∂x
(0, t) = 0.
(32)
From (31) we have M ′(t) > 0 and M ′′(t) < 0 for C0g > CE. This
behaviour is observed in Figure 8 where we plot the mass M(t) for
D = 0.05, CE = 0 when C0g = 0.5, 0.75.
(iii) There is no drug in the polymeric matrix at t=0 and CE = 0
In this case we have C0g = 0. From (28) we deduce
M(t) =
4DC0b
ℓ
∞∑
n=0
λ(an + λ)
[(an + λ)2 + λ2]
eant − 1
an
. (33)
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Figure 8. The mass M(t) for D = 0.05, CE = 0, C0g = 0.5, 0.75.
In this case as
M ′′(t) =
4DC0b
ℓ
∞∑
n=0
λan(an + λ)
(an + λ)2 + λ2
eant,
we cannot conclude the sign of the curvature. In fact an ≤ 0, n =
0, 1, . . . , but an + λ can be positive or negative, as we take the plus
sign or the minus sign in the second order equation (25). Observing
Figure 11 b we note that the plot of M(t) is S−shaped with the sign
of M ′′(t) inverting for some t¯ ∈ [5, 10].
In Figure 9 we plot the mass M(t) for D = 0.05, CE = C0g = 0 and
for λ = 0.01, 0.1. The released mass M(t) is an increasing function of
λ.
(iv) The lens has particles but they are not filled with drug at t=0 and
CE = 0.
We note that in this case C0b = 0 but λ 6= 0. From (28) we then
have
M(t) =
4DC0g
ℓ
∞∑
n=0
(an + λ)
2
(an + λ)2 + λ2
eant − 1
an
. (34)
We easily conclude from (34) that M ′(t) > 0 and M ′′(t) < 0.
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Figure 9. The mass M(t) for λ = 0.01 ((a)) and λ = 0.1 ((b)).
In Figure 10 we plot the mass M(t) for C0b = CE = 0, D = 0.05
when λ increases. As λ increases a decreasing of the released mass is
observed.
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Figure 10. The massM(t) as function of C0g for λ = 0 λ = 0.01
((a)) and λ = 0.05 ((b)).
Let us now compare (i) with (ii) and (iii) with (iv) :
• Comparison of the values of M(t) given by (i) and (ii)
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We assume that C0g − CE > 0. As an < 0 we have
(an + 2λ)(an + λ)
(an + λ)2 + λ2
eant − 1
an
≤
eant − 1
an
. (35)
In fact (35) is equivalent to
(an + 2λ)(an + λ) ≤ (an + λ)
2 + λ2 (36)
and finally to
anλ ≤ 0.
which is always satisfied. From (30), (31) and (35) we conclude that
for each t the total released mass is delayed in the case of a lens with
particles. This behaviour can be observed in Figures 7 and 8. In fact,
in Figure 7 the first curve (CE = 0, C0g = 0.5) presents a delay effect
when compared with the second curve of Figure 8 (CE = 0, C0g = 0.5).
• Comparison of M(t) given by (iii) and (iv)
In case (iii) there is no drug in the polymeric matrix at t = 0, this
means that all the drug is inside the particles. In case (iv) there is no
drug inside the particles at t = 0, and all drug is inside the polymeric
matrix. In order to compare the masses in the two cases we suppose
that in (iii) the initial drug concentration C0b in the particles is equal
to the initial drug concentration C0g in (iv).
All the terms of the series in (34)are positive. The terms of the
series (33) that correspond to taking a sign plus in (21) are positive
because an + λ ≥ 0; the terms corresponding to taking a sign minus
in (21) are negative because in this case an + λ ≤ 0.
Let us consider the terms for which an + λ ≥ 0. As an ≤ 0 we have
λ(an + λ) ≥ (an + λ)
2. (37)
For the terms for which an + λ ≤ 0 then
λ(an + λ) ≤ (an + λ)
2. (38)
From (37) and (38) it is clear that in a general case we can not
compare (33) and (34). However if λ is very small (an + λ) ≤ 0 and
consequently (38) holds. This means that the mass given by (34) is
larger than the mass given by (33). The plots of the mass M(t) in
Figures 9 and 10 exhibit this behaviour.
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In Figure 11 we plot the mass M(t) obtained with D = 0.05, λ =
0.1, CE = 0, and for C0g = 0.5, 0.75, C0b = 0 (Figure 11(a)) and
C0b = 0.5, 0.75, C0g = 0 (Figure 11(b)). A delayed effect is observed
when the drug is encapsulated in the particles.
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Figure 11. The mass M(t) for t ∈ [0, 50]: (a) C0g =
0.5, 0.75, C0b = 0; (b) C0b = 0.5, 0.75, C0g = 0.
4. Experimental results versus numerical simulation
In the previous section we consider the drug release model (1) with homoge-
neous Dirichlet boundary conditions (3) which means that the drug attaining
the boundary is immediately removed. Exact solution were computed and
the qualitative behaviour of such model was studied and illustrated. Our aim
in what follows is to simulate numerically the behaviour of model (1) under
more realistic assumptions and to compare the simulation with experimental
results.
As long as the drug is being released, some quantity still remains in the
neighborhood of the lens. This fact means that in a more realistic model the
homogeneous Dirichlet boundary conditions should be replaced by the Robin
boundary conditions

D
∂Cg
∂x
(−ℓ, t) = α1(C
g(−ℓ, t)− CE)
−D
∂Cg
∂x
(ℓ, t) = α2(C
g(ℓ, t)− CE), t > 0.
(39)
20 J.A. FERREIRA, P. DE OLIVEIRA, P. M. DA SILVA, A. CARREIRA, H. GIL AND J.N. MURTA
As a fraction of the released drug is absorbed by the eye, the exterior con-
centration should be assumed time dependent and depending on the concen-
tration at the boundary. We consider CE = γC0g(−ℓ, t).
An expression for the solution of the initial boundary value problem (1),
(2), (39) can be obtained using the procedure followed in the previous section.
As the computation of the solution Cg in this case is a tedious task we present
in what follows the numerical simulation of the mass M(t) obtained using a
standard finite difference discretization. In all figures we consider that time
is represented in the x-axis and that the amount of drug released by the lens
per unit volume of lens in the y-axis.
We begin by verifying that the model coupled with the new boundary con-
ditions still presents a delayed behaviour. In Figure 12 we plot the simulation
results obtained for the contact lenses with and without particles. In the nu-
merical simulation for the mass drug released from a contact lens without
particles Mdif(t) we considered
C0b = 0, λ = 0, C0g = 0.285, D = 0.2565× 10−3,
α1 = α2 = 0.05, γ = 0.5.
(40)
In the numerical simulation of the released massMnano(t) for the contact lens
with particles we used
C0b = 0.05102, λ = 0.02, C0g = 0.285,
α1 = α2 = 0.01, γ = 0.5.
(41)
and a time dependent Heaviside diffusion coefficient is considered to describe
the adaptation of the polymeric matrix to the drug delivery phenomena
D(t) =


0.1996× 10−3, t ∈ [0, 420]
0.9× 10−5, t ∈ (420, 11520].
(42)
We point out that the initial concentration of the drug dispersed in the
polymeric matrix and in the particles as well the diffusion coefficients char-
acterizing the contact lenses were determined by the experimental work. The
delay effect of the use of particles to retard the drug delivery it is well illus-
trated in this figure. In fact we observe that Mdif(t) attains the stationary
state at the first day while Mnano(t) still increasing at eighth day: some drug
remains inside of the polymeric matrix or/and in particles.
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Figure 12. Numerical masses delivery: Mdif(t), Mnano(t) ob-
tained with (40) and (41), (42) respectively.
In what follows we compare the experimental data with the simulation
results. In Figure 13 we present the plot of the mass M(t) released from the
lens when the drug is entrapped in the polymeric matrix. The numerical and
the experimental results, respectively Mn(t) and Me(t), were obtained with
(40). Several experimental and numerical simulations have been carried on
showing an agreement as can be seen in the example of Figure 13.
The experimental and numerical results for the contact lens for the case of
drug only entrapped in particles are plotted in Figure 14. In this case the
transfer time of the drug from the particles to the polymeric matrix and the
diffusion time have a central role on the initial behaviour. We take
C0b = 0.04075, C0g = 0,
α1 = α2 = 0.05, λ = 0.02, γ = 0.5,
(43)
and
D(t) =


0.19244× 10−2, t ∈ [0, 250]
0.189× 10−3, t ∈ (250, 540].
(44)
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Figure 13. Numerical and experimental mass delivery from a
lens with dispersed drug during the first 8 hours obtained with
(40).
The numerical predictions are very accurate as can be observed from the
fact that both experimental and numerical results present the same be-
haviour.
The experimental and numerical released masses when the drug is en-
trapped in the polymeric gel and in particles are plotted in Figure 15. We
consider
C0b = 0.05102, C0g = 0.28
α1 = α2 = 0.01, λ = 0.02, γ = 0.5
(45)
and
D(t) =


0.1996× 10−3, t ∈ [0, 300]
0.11× 10−4, t ∈ (300, 480].
(46)
The same qualitative behaviour of numerical and experimental results is
observed. From Figures 13 and 15 we conclude that the presence of particles
induces a delay effect on the delivery mass during 8 hours. The long term
behaviour of the lens when the drug is entrapped in the particles and in the
polymeric matrix is illustrated in Figure 16. In this case we consider the
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Figure 14. Numerical and experimental mass delivery from a
lens with entrapped particles loaded with the drug during the
first 9 hours obtained with (43) and (44).
coefficient diffusion defined by (42). The experimental data was well fitted
by the simulation results predicted by model (1), (2), (39).
5. Conclusions
In this paper a drug delivery system based on p-(HEMA/MAAA) copoly-
mer is proposed. The loading of copolymer contact lens was made by dis-
persing the drug in the the polymeric matrix by entrappement while the
monomers are polymerizing. Silicone particles encapsulating the ophthalmic
drug were dispersed in the polymeric matrix. This ”two barriers” delivery
system was studied from experimental and mathematical point of views.
When a simplified boundary conditions are assumed in the system of partial
differential equations a close form for the total released mass was obtained.
A qualitative analysis was then performed leading to a better understanding
of the dependence of the mass on the problem parameters as the diffusion
coefficient, the product of the mass transfer coefficient across the particles
surface and the ration between the surface and volume particles, the initial
concentrations in the polymeric matrix and in the silicone particles and the
drug transfer coefficients. In the case of more realistic boundary conditions,
24 J.A. FERREIRA, P. DE OLIVEIRA, P. M. DA SILVA, A. CARREIRA, H. GIL AND J.N. MURTA
0 100 200 300 400 500
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
t − min
       M
n
(t)
   *   M
e
(t)
Figure 15. Numerical and experimental mass delivery from a
lens with dispersed drug and entrapped particles loaded with
drug during the first 8 hours obtained with (45) and (46).
the model was solved numerically and the simulation showed a very good
agreement with experimental data.
The results obtained confirm that replacing a polymeric matrix with dis-
persed drug by a polymeric matrix with dispersed drug and with entrapped
particles loaded with drug leads to:
• a greater total loaded drug mass,
• a significant delay in the drug delivery,
• a continuous drug release,
when p-HEMA/MAA copolymer is used. This last characteristic means that
the released drug mass is strictly increasing. As mention before, this be-
haviour was not observed in [3] where a p-HEMA gel was used to entrap the
silica particles loaded with drug. The results obtained confirm that the sys-
tem studied in this paper can be a potential ophthalmic drug delivery vehicle.
Future work includes a wider experimental studies and in-vivo experiments.
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Figure 16. Numerical and experimental mass delivery from a
contact lens with dispersed drug and entrapped particles loaded
with drug during the first 8 days obtained with (45) and (42).
6. Appendix
Symbol Definition (units)
x Spatial variable (mm)
t time variable (min)
∂
∂x
Partial derivative with respect to x
∂2
∂x2
Second order partial derivative with respect to x
∂
∂t
Partial derivative with respect to x
Cg Drug concentration in the polymeric matrix (µg/mm3)
Cb Drug concentration in the silicone particles (µg/mm3)
CE Exterior drug concentration (µg/mm3)
C0g Initial drug concentration in the polymeric matrix (µg/mm3)
C0b Initial drug concentration in the silicone particles (µg/mm3)
D Diffusion coefficient in the polymeric matrix (mm2/min)
λ Product of the mass transfer coefficient across the particles surface
and the ration between the surface and volume particles (1/min)
2ℓ Thickness of the contact lens (mm)
α1 Drug transference coefficient at the right side of the contact lens (mm/min)
α2 Drug transference coefficient at the right side of the contact lens (mm/min)
M(t) Total mass released during t units of time.
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